Organised by SHC
The Science of HBV Cure Meeting 2026 LIVE
For Scientists, Clinician Scientists and
Pharmacists and Industry Experts
Asian HBV/HDV Endpoints Consensus Meeting
To View SHC 2026 Videos and Download PDF Slides:
To view the menu of slides and video recordings from any year, please click on the e-Resources tab.
If you wish to watch videos and download slides of past conferences up to SHC 2022, you must register or log in to the Website. Videos and Slides up to SHC 2022 are available free of charge.
If you had registered as a premium user in 2024, you will continue to have access to 2024 materials.
The Science of HBV Cure Meeting 2026 LIVE Scientific Programme
September, 2026
4
| Programme | Time (SGT) |
|---|---|
| Welcome Remarks by the Conference Chairman | 08:30 – 08:35 |
| Opening Symposium: Overview of HBV Functional Cure Moderators: Prof. Fabien Zoulim View Bio Prof. Jinlin Hou |
|
| HBV Cure: HBV Cure States from the Asian Consensus Conference – Prof. Seng Gee Lim, National University Health System, Singapore View Bio |
|
| Challenges to achieve functional cure Adj. Prof. Veronica Miller, UC Berkeley, Public Health, USA View Bio |
|
| Landscape of functional cure 2026 after Bepirovirsen phase 3 results – Prof. Fabien Zoulim, Universite Claude Bernard Lyon 1, France View Bio |
|
| Q&A | 09:30 – 09:45 |
| Tea Break | 09:45 – 10:15 |
| Opening Symposium: Overview of HBV Functional Cure Moderators: Prof. Fabien Zoulim View Bio Prof. Jinlin Hou |
|
| Free paper: Clinically meaningful functional cure rates in virologically suppressed Chinese patients with chronic hepatitis B virus infection treated with bepirovirsen: A subanalysis of the B-Well Phase 3 trials, Prof. Jin Lin Hou, Nanfang University, Guangzhou, China |
|
| Free paper: Projected impact of hepatitis B virus functional cure therapies on liver disease burden in China: A modelling analysis, Dr. Devin Razavi-Shearer |
|
| Free paper: Metabolic Dysfunction and Its Impact on Chronic Hepatitis B Progression Hepatitis B Functional Cure: Real-World Clinical Perspectives, Dr. Preeti, Agarwal |
|
| Q&A | 11:00 – 11:15 |
| Virological Insights into functional cure Moderators: Prof. Thomas Tu View Bio |
|
| Virological Cure and complete cure: achievable or imaginary? – Prof. Massimo Levrero, Universite Claude Bernard Lyon 1, France View Bio |
|
| Integrated HBV: what’s important? Burden, integration site or clonal expansion – Prof. Thomas Tu, Westmead Institute for Medical Research, Australia View Bio |
|
| Free paper : Intrahepatic viral integration more than reservoir size dictates the HBsAg loss trajectory in Chronic Hepatitis B, Dr. Cameron Soulette Gilead Science Inc |
|
| Q&A | 12:10 – 12:20 |
| Lunch | 12:20 – 13:20 |
| Intrahepatic microenvironment Moderator: Prof. Massimo Levrero View Bio |
|
| Spatial transcriptomics: state of the Science and Art – Charting the Spatial Whole Transcriptome and Multiomic Frontier for Complete Biology Dr. Prajan Divakar, Bruker Corporation |
|
| Spatial proteomics: Advancements in cyclic immunofluorescence methods for liver tissue imaging and spatial profiling enabled by the CellScape XR platform. Dr. Benton Berigan, Bruker Corporation |
|
| Spatial Transcriptomics in HBV – Prof. Jane McKeating, Oxford |
|
| Intrahepatic immune correlates of functional cure – Prof. Adam Gehring, University of Toronto, Canada View Bio |
|
| Free paper: Spatial Transcriptomics of CHB and HBsAg loss using CosMx, Dr. Aravind Sivakumar et al |
|
| Q&A | 14:35 – 14:50 |
| Animal Models Moderator: Prof. Qingfeng Chen View Bio |
|
| Benefits and limitations of animal models to assess antivirals and immune modulators for Functional Cure. Prof. Maura Dandri, University Medical Center Hamburg-Eppendorf Germany View Bio |
|
| Free paper: Impact of Bulevirtide on Hepatocyte Transcriptional Programs in a Humanized Mouse Model of HDV Infection. Dr. Wakae Kousho (abstract 48) |
|
| Q&A | 15:30 – 15:45 |
| Tea Break | 15:45 – 16:00 |
| Strategies with existing agents Moderator: Prof. Man Fung Yuen View Bio |
|
| Stopping nucleoside analogues: is there still a role in FC? – Prof. Norah Terrault, Keck School of Medicine, University of Southern California. View Bio |
|
| Peginterferon: never say die – Prof. Teerha Piratsuvith, Prince of Songkla University, Thailand View Bio |
|
| Free paper To Stop or Not to Stop? End-of-Treatment HBcrAg for Predicting Relapse After Nucleos(t)ide Analogue Cessation in Chronic Hepatitis B: A Diagnostic Test Accuracy Meta-Analysis. Budiman et al (abstract 35) | |
| Q&A | 17:00 – 17:15 |
| End of day 1 | 17:15 |
September, 2026
5
| Programme | Time (SGT) |
|---|---|
| Biomarkers Moderators: Prof. Teerha Piratvisuth View Bio |
|
| HBsAg levels in real world and for clinical trials of novel therapies – Prof. Man-Fung Yuen, Hong Kong View Bio |
|
| Biomarkers that corelate with cccDNA – Prof. Jordan Feld, University of Toronto, Canada View Bio |
|
| Using Biomarkers for management of CHB with novel therapies – Prof. Yasuhito Tanaka, Kumamoto University View Bio |
|
| Q&A | 09:30 – 09:40 |
| RNA interference Moderators: Prof. Mala Maini View Bio |
|
| Anti-sense oligonucleotides: are they immune modulators? – Prof. Antonio Bertoletti, Duke NUS Graduate School of Medicine, Singapore View Bio |
|
| The role of siRNA in HBV cure therapies – Prof. MF Yuen, Hong Kong University, Hong Kong View Bio |
|
| Q&A | 10:20– 10:30 |
| Tea Break | 10:30 – 10:45 |
| Poster Presentation Moderated by Dr. Lee Yin Mei (NUHS) |
|
| Delta Cure Moderator: Prof. Pietro Lampertico View Bio |
|
| Delta Cure update – Prof. Heiner Wedemeyer, Hannover Medical School, Germany View Bio |
|
| Novel therapeutics for Delta Cure Prof. Pietro Lampertico, Italy View Bio |
|
| Q&A | 11:55 – 12:05 |
| Lunch | 12:05 – 13:10 |
| Invited Pharma Presentations Moderators: Prof. Lim Seng Gee View Bio and Prof. Adam Gehring View Bio |
|
| Bepirovirsen: The Journey So Far Attila Mihalyi (Vice President, Global Medical Lead, Hepatitis B) GSK |
|
| AHB-137, update Dr. Guo Feng Cheng, CEO, Ausperbio Therapeutics Inc |
|
| siRNA+Neutralizing antibody – Dr. Wu Kai, CEO, Hepa Thera Biopharmaceutical Co., Ltd |
|
| VRON-0200: Priming Immunity for CHB Cure: A Clinical Update Dr. Sue Currie, COO, Virion Therapeutics LLC |
|
| Q&A | 14:10 – 14:20 |
| Immunology Moderator: Prof. Antonio Bertoletti View Bio |
|
| The challenges and promise of immune modulation for Functional Cure – Prof. Mala Maini, University College London, UK View Bio |
|
| Antibody therapeutics in the quest for Functional Cure – Prof. Adam Gehring, University of Toronto, Canada View Bio |
|
| Free paper: Characterisation and discovery of epitopes of anti-HBe during HBeAg seroconversion, Dr. Low Heng Boon, National University of Singapore |
|
| Free paper: Peg-interferon modulates the trajectory of peripheral immunity in functionally cured chronic hepatitis B patients, Dr. Neo Shi Yong (Singapore Immunology Network, A*Star) et al (abstract 26) |
|
| Free paper: First-in-Human Safety of the Dendritic Cell–Targeting Immunotherapy SN2001 with Translational Evidence Supporting Restoration of HBV-Specific Cellular Immunity, Yuenian Eric Shi et al (CEO, Chimegen bio) (abstract 50) |
|
| Q&A | 15:45 – 16:00 |
| Tea Break | 16:00 – 16:15 |
| Gene Therapy Moderators: Prof. Fabien Zoulim View Bio |
|
| Early clinical results of gene/epigenetic editing – Prof. Ed Gane, University of Auckland, New Zealand View Bio |
|
| The safety of gene editing: What to measure and for how long? – Dr. Wei Leong Chew GIS, ASTAR View Bio |
|
| Q&A | 16:55 – 17:10 |
| Closing remarks from Chairman | 17:10 – 17.15 |